Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis

(2019) Teresa Amaral et al.   Immunotherapy

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy‐Mediated Systemic Control

(2019) Christopher Alvarez‐Breckenridge et al.   ONCOLOGIST

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases

(2019) Ricarda Rauschenberg et al.   EUROPEAN JOURNAL OF CANCER

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort

(2019) Pauline Tétu et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

(2019) Hussein Abdul-Hassan Tawbi et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.

(2019) Philippe Saiag et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).

(2019) Maria Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

(2019) Giuseppe Minniti et al.   Journal for ImmunoTherapy of Cancer

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis

(2019) Eliana Rulli et al.   CANCER

Clinical prognostic factors associated with survival and a survival score for patients with brain metastases

(2019) Patricia Șuteu et al.   Future Oncology

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

1327PClinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts)

(2019) I Pires da Silva et al.   ANNALS OF ONCOLOGY

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

(2019) Margreet G. Franken et al.   EUROPEAN JOURNAL OF CANCER

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

(2018) Georgina V Long et al.   LANCET ONCOLOGY

Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases

(2018) Charlee Nardin et al.   MELANOMA RESEARCH

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy

(2018) Martin Tio et al.   Pigment Cell & Melanoma Research

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients

(2018) Anissa Roger et al.   OncoImmunology

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

(2018) Harriet M. Kluger et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma

(2018) Susanne Stera et al.   MELANOMA RESEARCH

Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters

(2018) Heinz Schmidberger et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies

(2017) Ee Siang Choong et al.   EUROPEAN JOURNAL OF CANCER

Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis

(2017) T. Gambichler et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

(2017) Erik S. Anderson et al.   Journal for ImmunoTherapy of Cancer

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

(2016) Jack M. Qian et al.   CANCER

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

(2015) K. A. Ahmed et al.   ANNALS OF ONCOLOGY

Radiotherapy Complements Immune Checkpoint Blockade

(2015) Shin Foong Ngiow et al.   CANCER CELL

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

(2015) Ravi A Chandra et al.   OncoImmunology

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

(2014) A. B. Sharabi et al.   Cancer Immunology Research

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Determinants of survival in patients with brain metastases from cutaneous melanoma

(2010) M Staudt et al.   BRITISH JOURNAL OF CANCER

Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma

(2010) Thomas K. Eigentler et al.   CANCER